Folic acid revisited

Indian Journal of Pharmacology

Volumn 33, Issue 5, 2001, Pages 322-342

  Hazra, Avijit ^a   Tripathi, Santanu Kumar ^b  

^a MEDICAL COLLEGE AND HOSPITAL   (India)

^b NRS MEDICAL COLLEGE   (India)

Author keywords

Folic acid; Food fortification; Homocysteine; Macrocytic anemia; Neural tube defect

Indexed keywords

ANDROGEN; ANTACID AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; ASCORBIC ACID; CARNITINE; CHLORAMPHENICOL; COLESTYRAMINE; CYANOCOBALAMIN; CYTOKINE; ESTROGEN; FOLIC ACID; FOLIC ACID ANTAGONIST; FOLINATE CALCIUM; IRON; METHOTREXATE; MULTIVITAMIN; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; PLACEBO; PROGUANIL; PYRIMETHAMINE; TRIAMTERENE; TRIMETHOPRIM; TRIMETREXATE; UNINDEXED DRUG; VITAMIN D;

AGE; ALCOHOLISM; ANTINEOPLASTIC ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CEREAL; CLEFT LIP FACE PALATE; CLINICAL TRIAL; DIET SUPPLEMENTATION; DNA SYNTHESIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COST; DRUG ELIMINATION; DRUG INDICATION; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG USE; DRUG UTILIZATION; ERYTHROPOIESIS; FOLIC ACID DEFICIENCY; FOOD; GASTROINTESTINAL SYMPTOM; GERIATRIC PATIENT; HEMODIALYSIS; HEMOLYTIC ANEMIA; HUMAN; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE; LACTATION; MACROCYTIC ANEMIA; MALABSORPTION; MALNUTRITION; MEGALOBLASTIC ANEMIA; META ANALYSIS; NEURAL TUBE DEFECT; NEUROLOGIC DISEASE; NONHUMAN; NUTRITION; NUTRITIONAL REQUIREMENT; PREGNANCY; PROPHYLAXIS; REVIEW; RHEUMATOID ARTHRITIS; SEIZURE; TERATOGENICITY; TOTAL PARENTERAL NUTRITION; VITAMIN SUPPLEMENTATION;

EID: 0035156525     PISSN: 02537613     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (114)

1. A new factor in the production and cure of macrocytic anemia and its relation to other haemopoietic principles curative in pernicious anemia
2. Folic acid
3. Structure and function of the water-soluble vitamins
4. Compatibility and stability of TPN mixtures in big bags
5. Folates and dairy products: A critical update
6. Polymorphisms of methylene-tetrahydrofolate reductase and other enzymes: Metabolic significance, risks and impact on folate requirement
7. Molecular biology of 5,10-methylene-tatrahydrofolate reductase
8. Hematopoietic agents: Growth factors, minerals and vitamins
9. Folate metabolism and requirements
10. Dietary reference intakes for folate: The debut of dietary folate equivalents
11. Accelerated folate breakdown in pregnancy
12. New standard for dietary folate intake in pregnant women
13. Folate and health - New knowledge and new recommendation
14. Folic acid for the prevention of neural tube defects
15. Fortified foods and folate intake in women of child-bearing age
16. Prevention of neural tube defects
17. Drug and environmental factors associated with adverse pregnancy outcomes. Part III: Folic acid: Pharmacology, therapeutic recommendations, and economics
18. Fighting about folate
19. Folic acid, pernicious anaemia, and prevention of neural tube defects
20. Folate deficiencies and cardiovascular pathologies
21. Modern clinical testing strategies in cobalamin and folate deficiency
22. Carrier-mediated membrane transport of folates in mammalian cells
23. Recent advances in the understanding of the mechanism of membrane transport of folates and antifolates
24. Folate-mediated targeting of therapeutic and imaging agents to cancers
25. Folae-mediated targeting of antineoplastic drugs, imaging agents, and nucleic acids to cancer cells
26. High-dose folic acid treatment for red-cell aplasia
27. Anemia in pregnancy
28. Anemia in pregnancy
29. Folic acid: Influence on the outcome of pregnancy
30. Iron and folate supplementation in pregnancy
31. Folate supplementation in pregnancy
32. Nutritional interventions for the prevention of maternal morbidity
33. Ambulatory management of multiple gestation
34. Folic acid in the prevention of neural tube defects
35. Double-blind randomised controlled trial of folate treatment before conception to prevent recurrence of neural tube defects
36. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation
37. Periconceptional folic acid exposure and risk of occurrence of neural tube defects
38. Urgent need to increase folic acid consumption
39. Prevention of neural tube defects: Results of the Medical Research Council vitamin study
40. Periconceptional supplementation with folate and/or multivitamins for preventing neural tube defects
41. The role of folate transport and metabolism in neural tube defect risk
42. How folic acid might prevent neural tube defects
43. Vitamins and brain development
44. Response of red blood cell folate to intervention: Implications for folate recommendations for the prevention of neural tube defects
45. Recommendations for use of folic acid to reduce number of spina bifida cases and other neural tube defects
46. Effect of increasing dietary folate on red-cell folate
47. Use of folic acid for prevention of spina bifida and other neural tube defects - 1983-1991
48. A randomised trial of low dose folic acid to prevent neural tube defects
49. Folate levels and neural tube defects: Implications for prevention
50. Drug and environmental factors associated with adverse pregnancy outcomes. Part II: Improvement with folic acid
51. Prevention of congenital abnormalities by periconceptional multivitamin supplementation
52. Environment and genetics in the etiology of cleft lip and cleft palate with reference to the role of folic acid
53. The role of folic acid in oral clefting
54. Risks of orofacial clefts in children born to women using multivitamins containing folic acid periconceptionally
55. Neurologic care of pregnant women with epilepsy
56. Epilepsy and pregnancy
57. Epilepsy and pregnancy
58. Treatment of epilepsy in pregnancy
59. Should all elderly people receive folate supplements?
60. 12 and folate
61. Drug-nutrient interaction
62. 12 status
63. Vitamin replacement therapy in renal failure patients
64. Optimizing erythropoietin therapy
65. 12 supplementation necessary in chronic hemodialysis patients with EPO treatment
66. Folate deficiencies and cardiovascular pathologies
67. Hyperhomocysteinaemia as a cardiovascular risk factor: An update
68. Plasma homocysteine as a cardiovascular risk factor: Causal, consequential, or of no consequence?
69. Homocysteine and ischemic heart disease: Results of a prospective study with implications regarding prevention
70. Homocysteine as a risk factor for atherosclerosis
71. Homocysteine as a novel risk factor for atherosclerosis
72. Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomised trials
73. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes
74. Folate and carcinogenesis: An integrated scheme
75. Folic acid deficiency and cancer: Mechanisms of DNA instability
76. European trials on dietary supplementation for cancer prevention
77. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. Advanced Colorectal Meta-Analysis Project
78. Treatment of advanced colorectal cancer with 5-fluorouracil and interferon-alpha: An overview of clinical trials
79. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer
80. Folate and cancer prevention: A new medical application of folate beyond hyperhomocysteinemia and neural tube defects
81. Micronutrients prevent cancer and delay aging
82. Does folate supplementation make sense in patients with rheumatoid arthritis treated with methotrexate?
83. Folic acid supplementation during methotrexate therapy: It makes sense
84. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A meta-analysis of randomized controlled trials
85. Methotrexate and folates in rheumatoid arthritis
86. The fragile-X syndrome
87. Folic acid treatment of fragile X males: A further study
88. Double-blind, placebo-controlled crossover study of folinic acid (leucovorin) for the treatment of fragile X syndrome
89. Folic acid deficiency related to the use of goat milk for infant feeding
90. Folate deficiency in the myeloproliferative disorders
91. How safe are folic acid supplements?
92. 12 and folate
93. Benzyl alcohol toxicity impact on mortality and intraventricular hemorrhage among very low birth weight infants
94. Drugs and folate metabolism
95. Macrocytic anemia in patients treated with sulphasalazine for rheumatoid arthritis
96. Phenytoin-folic acid interaction: A lesson to be learned
97. Folic acid safety and toxicity: A brief review
98. Effects of folic and folinic acids in the activities of cycloguanil and WR99210 against Plasmodium falciparum in erythrocytic culture
99. Effect of antacid and H2 receptor antagonists on the intestinal absorption of folic acid
100. Appendix 1: Drug interactions
101. Drug interactions with oral contraceptives
102. Effect of oral folic acid supplements on zinc, copper, and iron absorption and excretion
103. Zinc concentration in plasma and erythrocytes of subjects receiving folic acid supplementation